<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603083</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2007-003890-20</org_study_id>
    <secondary_id>S-20070066</secondary_id>
    <nct_id>NCT00603083</nct_id>
  </id_info>
  <brief_title>Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia</brief_title>
  <official_title>Postoperative Pain Treatment in Total Hip Arthroplasty A Randomized Double-blinded Placebo-controlled Study to Assess the Effect of Local Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the investigator standardized pain
      treatment plus local pain treatment is more effective than the investigator standardized pain
      treatment plus placebo in total hip arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting (PONV)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>2 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, Ketorolac and Adrenalin</intervention_name>
    <description>The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Naropin</other_name>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for an uncemented unilateral Total Hip Replacement because of osteoarthritis

          -  Willingness and possibility to follow the instructions of the study

          -  18 years or older

          -  written informed consent and authority after it has been read and understood.

        Exclusion Criteria:

          -  Operation with anterior approach or using navigation

          -  Do not understand or speech danish

          -  Can not use the pain-score Numerical Rating Scale (NRS)

          -  Special indications for Total Hip Replacement

          -  Anaesthetized in general anaesthesia where a tube is demanded

          -  Daily use of strong opioids, based on the investigators assessment

          -  Fertile women

          -  ASA-score: 3 and 4

          -  Known allergy against the standardized pain treatment, the study drugs and placebo,
             Ropivacaine, Ketorolac, Adrenalin.

          -  Treatment with Lithium, Dihydroergotamin, full anticoagulant treatment or
             MAO-inhibitor

          -  Following illness:

          -  Active gastric ulcer or earlier gastrointestinal bleeding, ulceration or perforation
             of any kind.

          -  Suspicions of manifest gastrointestinal bleeding and/or cerebrovascular bleeding

          -  Haemorrhagic diathesis

          -  Coagulation disorder

          -  Severe thrombocytopenia

          -  Severe heart insufficiency

          -  Severe risk of postoperative bleeding or delayed haemostatic

          -  Myocardium hypertrophy or ischaemic heart disease

          -  Hypertension

          -  Hypovolemics

          -  Anhydration

          -  angiooedema

          -  Asthma

          -  Bronchospasm

          -  Severe liver insufficiency

          -  Rhinostenosis because of polyostotic

          -  Narrow-angled glaucoma

          -  Phaeochromocytoma

          -  Low plasm-potassium

          -  Thyreotoxicosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Kjaersgaard-Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ortopaedic Department, Vejle Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopaedic Department</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopaedic Department, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>December 8, 2011</last_update_submitted>
  <last_update_submitted_qc>December 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vejle Hospital</investigator_affiliation>
    <investigator_full_name>Per Kjaersgaard-Andersen</investigator_full_name>
    <investigator_title>Per Kjaersgaard-Andersen MD</investigator_title>
  </responsible_party>
  <keyword>Hip Arthroplasty</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Local Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

